About this course

  • Released: 11/20/2017
  • Expires: 11/20/2019

Instructions

  • Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
  • Study the educational activity
  • Complete the CME quiz and evaluation
  • After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

*The CME quiz and evaluation must be completed by November 20, 2019 in order to receive the credit or participation certificate.

Target Audience

Physicians who wish to advance their current knowledge of community outreach in oncology.

Learning Objectives

  1. Discuss disparities in breast cancer outcomes for patients with schizophrenia and lack of access to psychosocial services that are integrated into cancer care.
  2. Describe the frequency and type of cancer care disruptions in a population of patients with schizophrenia and breast cancer.
  3. Identify potential risk factors for breast cancer care disruptions for patients with schizophrenia, including lack of documented psychiatric treatment and antipsychotic medication.

Accreditation and Credit Designation

The Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians.

The Society for Translational Oncology designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy

In compliance with the ACCME Standards of Commercial Support, it is the policy of the Society for Translational Oncology to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities and to include information free of commercial bias and based on the best evidence available. All individuals in a position to influence the content of this activity have disclosed relevant financial interests or relationships of their own, their spouse/partner, or their worksite, with manufacturers or providers of commercial products, services, technology, or programs; and disclosed relationships with current non-governmental supporters of the activity.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process: http://authors.theoncologist.com/conflicts-of-interest. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Author Disclosure(s)

Kelly E. Irwin

Department of Psychiatry, Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA

The author discloses no relevant financial interests.

Elyse R. Park

Benson-Henry Institute for Mind Body Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA

The author discloses no relevant financial interests.

Jennifer A. Shin

Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA

The author discloses no relevant financial interests.

Lauren E. Fields

Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA

The author discloses no relevant financial interests.

Jamie M. Jacobs

Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA

The author discloses no relevant financial interests.

Joseph A. Greer

Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA

The author discloses no relevant financial interests.

John B. Taylor

Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA

The author discloses no relevant financial interests.

Alphonse G. Taghian

Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA

The author discloses a consulting relationship with VisionRT.

Oliver Freudenreich

Department of Psychiatry, Schizophrenia Clinical and Research Program, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA

The author discloses no relevant financial interests.

David P. Ryan

Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA

The author discloses honoraria received from MPM Capital.

William F. Pirl

Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA

The author discloses no relevant financial interests.

 

Section Editors Disclosures

Michele Evans discloses no relevant financial interests.

Beverly Moy discloses consulting relationships with Olympus and MOTUS GI.

 

Independent Peer Reviewers Disclosures

Reviewer 1 discloses no relevant financial interests.

 

CME Activity Director Disclosures

Jayne S. Gurtler, M.D., F.A.C.P., CME Program Editor, East Jefferson General Hospital, Metairie, Louisiana, discloses research funding from Chiltern, EMD Serono, Merck, Novartis, and TransCelerate.

 

Staff Planners Disclosures

No financial relationships relevant to the content of this article have been disclosed by the staff planners.

 

Commercial Support

The Editors are grateful for an educational grant from Merrimack in partial support of our Journal CME Program.

 

Other Links

Disclaimer Privacy statement

Correspondence

The Oncologist CME Online
318 Blackwell Street, Suite 270
Durham, North Carolina 27701
Phone: (919) 433-0489
Fax: (919) 680-4411
Email: CME@TheOncologist.com